Pharmaceutical News

RSS

Study provides guidelines on how to combine antiangiogenic drugs with nanotherapeutics

Combining two strategies designed to improve the results of cancer treatment - antiangiogenesis drugs and nanomedicines - may only be successful if the smallest nanomedicines are used. A new study from Massachusetts General Hospital (MGH) researchers, appearing in Nature Nanotechnology, finds that normalizing blood vessels within tumors, which improves the delivery of standard chemotherapy drugs, can block the delivery of larger nanotherapy molecules.

10 Apr 2012

Study finds successful weight loss strategies for obese people

A third of Americans are now obese, and up to 70% of them are trying to lose weight. In a new study published in the American Journal of Preventive Medicine, researchers from Harvard Medical School and Beth Israel Deaconess Medical Center in Boston have found in a nationally representative sample that obese dieters who said they ate less fat, exercised more, and used prescription weight loss medications were more likely to lose weight.

10 Apr 2012

FDA grants Fast Track designation to EpiCept's AmiKet

EpiCept Corporation announced today that AmiKet (amitriptyline 4%, ketamine 2% cream) has been granted Fast Track designation by the U.S. Food and Drug Administration.

10 Apr 2012

FDA approval of OMONTYS triggers $50M milestone payment to Affymax

Affymax, Inc. today announced that it has received a $50 million development milestone payment from Takeda Pharmaceutical Company as part of the companies' exclusive global agreement to develop and commercialize OMONTYS (peginesatide) Injection.

10 Apr 2012

Mayo Clinic introduces Breast Cancer Genome Guided Therapy Study

The Breast Cancer Genome Guided Therapy Study (BEAUTY Project) will help physicians tailor chemotherapy to breast cancer patients based on their individual genomes and the genomes of their tumors.

10 Apr 2012

RegeneRx wins four patents in Israel, Mexico

RegeneRx Biopharmaceuticals, Inc. announced today that the Company has received an issued patent in Mexico and allowances of three additional patent applications in Mexico and Israel.

10 Apr 2012

HDS signs LOI with PharmaLife to market Clotamin in Russia

Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC are pleased to announce that HDS has signed a Letter of Intent with PharmaLife for placement of Clotamin with leading pharmacies in the Russian Federation.

10 Apr 2012

OphthaliX completes CF101 preclinical studies on Anterior Uveitis

OphthaliX announced today the completion of preclinical studies, showing that its CF101 drug candidate is efficacious in treating Anterior Uveitis

10 Apr 2012

Prescriptions on the rise for strongest pain pills

High-strength painkillers known as opioids represent the most widely prescribed class of medications in the United States.

9 Apr 2012

Survey finds high rating for Heraeus iBOND Self Etch bonding agent

Heraeus Kulzer, LLC, the worldwide leader in dental esthetics, announced today that its iBOND Self Etch bonding agent received the maximum possible "5-plus" rating from THE DENTAL ADVISOR. The iBOND Self Etch bottle kit was evaluated by 26 consultants in 648 uses and received a very impressive 96% clinical rating.

9 Apr 2012

TherapeuticsMD introduces second prescription prenatal vitamin

TherapeuticsMD, Inc., parent company of vitaMedMD, LLC, a specialty pharmaceutical company, announced that on April 9, 2012 it launched its second prescription prenatal vitamin, vitaMedMD One Rx, following the successful launch of vitaMedMD Plus Rx last month.

9 Apr 2012

Idaho's adoption of NPLEx to block illegal methamphetamine sales receives praise

The Consumer Healthcare Products Association (CHPA) today applauded Idaho Governor C.L. "Butch" Otter for signing into law real-time, stop-sale technology called the National Precursor Log Exchange (NPLEx) which allows check-out clerks to block illegal pseudoephedrine purchases right at the point of sale and provides law enforcement with valuable criminal data up to the minute.

9 Apr 2012

Pacira launches EXPAREL in the U.S.

Pacira Pharmaceuticals, Inc. today announced the commercial launch of EXPAREL (bupivacaine liposome injectable suspension) in the United States. Starting today, EXPAREL will begin shipping to hospital and ambulatory care customers through their normal wholesaler and distributor channels.

9 Apr 2012

KU researchers receive inventorship credit on NIH-owned Velcade patents

Pillsbury today announced that its clients, the University of Kansas and the University of Kansas Center for Research, Inc., a nonprofit corporation affiliated with KU, prevailed in a closely watched legal battle over cancer drug formulation patents after an arbitration panel ruled in KUCR's favor following years of litigation against the National Institutes of Health.

7 Apr 2012

Sangui patent-based chronic wound spray now available

Based on a patent by Sangui, the technology for a spray aiming at improved healing of chronic wounds is now available. According to a notification by SastoMed GmbH a certification as class III medical product was granted. Global licensee SastoMed will be in charge of marketing and distribution.

7 Apr 2012

Study shows artemisinin-resistant malaria parasite spreading along Thai-Myanmar border

A strain of malaria that is resistant to artemisinin combination therapy (ACT) is spreading along the Thai-Myanmar border and has the potential to spread to Africa if efforts to effectively treat and prevent the disease are not undertaken, according to a study published in the Lancet on Friday, Reuters reports.

7 Apr 2012

NORD, Corcept partner to establish Cushing's Syndrome Patient Assistance Program

In partnership with Corcept Therapeutics Inc., the National Organization for Rare Disorders (NORD) has established a Cushing's Syndrome Patient Assistance Program for patients with endogenous Cushing's syndrome who need financial assistance with certain costs related to their medical diagnosis and/or care.

7 Apr 2012

No one funding model is sufficient to ensure availability of life-saving drugs

"Trade deals are threatening generic drugs -- we need new ways to incentivize affordable drug development," Daniele Dionisio, head of the research project Geopolitics, Public Health and Access to Medicines (GESPAM) and a member of the European Parliament Working Group on Innovation, Access to Medicines and Poverty-Related Diseases, writes in this SciDev.Net opinion piece.

7 Apr 2012

Par Pharmaceutical commences shipment of modafinil tablets

Par Pharmaceutical Companies, Inc. today announced that it began shipping all strengths of modafinil tablets, a generic version of Teva's Provigil brand.

7 Apr 2012

Lilly, Avid receive FDA approval for Amyvid to treat Alzheimer's

Eli Lilly and Company and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced the U.S. Food and Drug Administration (FDA) approval of Amyvid, a radioactive diagnostic agent indicated for brain imaging of beta-amyloid plaques in patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive decline.

7 Apr 2012